Faruqi and Faruqui, LLP Logo
Share this page

Cocrystal Pharma, Inc. (COCP)

NASDAQ:COCP

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Cocrystal Pharma, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Cocrystal Pharma, Inc. (“Cocrystal” or the “Company”) (NASDAQ:COCP) f/k/a BioZone Pharmaceuticals, Inc. (“BioZone”) of the November 19, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Cocrystal stock or options between September 23, 2013 and September 7, 2018 and would like to discuss your legal rights, please fill out the form below.  There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

The lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all those who purchased Cocrystal and/or BioZone securities between September 23, 2013 and September 7, 2018 (the “Class Period”).  The case, Pepe v. Cocrystal Pharma, Inc. f/k/a BioZone Pharmaceuticals, Inc. et al, No. 2:18-cv-14091 was filed on September 20, 2018.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) the company and certain of its officers were engaged in a pump-and-dump scheme to artificially inflate Cocrystal's stock price; (2) this illicit scheme would result in governmental scrutiny, including from the U.S. Securities and Exchange Commission (“SEC”); (3) the Company failed to abide by SEC disclosure regulations; and (4) as a result, the Company’s statements about Cocrystal's business, operations and prospects were materially false and misleading.

Specifically, on September 7, 2018, the SEC filed a lawsuit against Phillip Frost, one of the Company’s directors and shareholders, and others, alleging violations of the federal securities laws. According to the SEC’s complaint, Phillip Frost allegedly participated in at least two unlawful pump-and-dump schemes involving various microcap companies.

After the lawsuit was announced, Cocrystal’s share price fell from $3.74 per share on September 6, 2018, to a closing price of $3.16 on September 11, 2018—a $0.58 or a 15.51% drop.

Contact Us

To contact Faruqi & Faruqi, LLP please call (877) 247-4292 or (212) 983-9330, or please
fill out the form below and a Firm representative will contact you.

  • Case:
    Cocrystal Pharma, Inc. (COCP)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 09/21/2018

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.